Hepion Pharmaceuticals
Presence
Hepion Pharmaceuticals is a company listed under the stock ticker HEPA (US).
Executives
View the org chart displaying its 12 main executives
Most searched biographies at Hepion Pharmaceuticals
- John Cavan, Chief Financial Officer and Interim Chief Executive Of...
- Gary Jacob, Chairman of the Board
- John Brancaccio, Director
Popular executive movements at Hepion Pharmaceuticals
- Michael Purcell has joined the company as Director (posted on March 7 2024).
- Robert Foster, Chief Executive Officer and Director, has left the company (posted on December 7 2023).
- John Cavan, who was Chief Financial Officer, is promoted to Chief Financial Officer and Interim Chief Executive Officer (posted on December 7 2023).
Click here to view some more movements at Hepion Pharmaceuticals
Create your alert
to follow the executive moves at Hepion Pharmaceuticals.
Pharmaceuticals
Hepion Pharmaceuticals has 1,868 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Hepion Pharmaceuticals
- Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds – Hepion Pharmaceuticals
- Hepion Pharmaceuticals to Present at NASH-TAG 2024 – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes – Hepion Pharmaceuticals
- Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat – Hepion Pharmaceuticals
- Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model – Hepion Pharmaceuticals
- Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer – Hepion Pharmaceuticals
- New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program – Hepion Pharmaceuticals
- View more press releases Close
Social media about Hepion Pharmaceuticals
- Hepion Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Hepion Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including John Cavan 
Call Hepion Pharmaceuticals at +1 212...
